VIDEO: Tremfya produces clinical, endoscopic response in Crohn’s disease

In this exclusive video, William J. Sandborn, MD, from the University of California, San Diego, discusses interim results from the phase 2 GALAXI 1 study of Tremfya in patients with Crohn’s disease.In the study, researchers explored the efficacy and safety of three different doses of the drug (guselkumab, Janssen) against placebo, as well as a reference comparator, Stelara (ustekinumab, Janssen).All three doses induced greater improvements in clinical and endoscopic outcomes compared with placebo, according to Sandborn.Read More

Share on facebook
Share on twitter
Share on linkedin